Site‐Specific Construction of Long‐Term Drug Depot for Suppression of Tumor Recurrence

Abstract

Local tumor recurrence after surgical resection is a critical concern in cancer therapy, and the current treatments, such as postsurgical chemotherapy, still show undesired side effects. Here a nonimplant strategy (transformation induced localization, TIL) is presented to in situ construct long‐term retentive drug depots, wherein the sustained drug release from fibrous drug depots results in highly efficient suppression of postsurgical local tumor relapse. The peptide‐based prodrug nanoparticles show favorable tumor targeting and instantly reorganize into fibrous nanostructures under overexpressed enzyme, realizing the construction of long‐term drug depot in the tumor site. After the resection surgery, the remnant cancer cells are still inhibited by the sustained drug release from the fibrous prodrug depot, effectively preventing postsurgical local recurrences. This TIL strategy shows great potential in cancer recurrence therapy and offers a novel perspective for constructing functional biomaterials in vivo.

Nanoscale Copper(II)–Diethyldithiocarbamate Coordination Polymer as a Drug Self-Delivery System for Highly Robust and Specific Cancer Therapy

“…Compared with other nanoparticles, the nanoscale coordinating polymers are featured with unique properties such as high porosity and oriented structure, , which can encapsulate or absorb a wide range of bioactive ligands for drug delivery, − protein immobilization, − and bioimaging. , As a proof-of-concept, we tested this property by loading different molecules, including doxorubicin (DOX) and various fluorescent dyes (such as RhB, 5-FAM, and Cy7) into CuET NPs (Figure S2A). Interestingly, regardless of the physiochemical properties, all of these chemicals were successfully encapsulated with high loading efficiency (Figure S2B).…”

In Situ Constructed Nano‐Drug Depots through Intracellular Hydrolytic Condensation for Chemotherapy of Bladder Cancer

“…After confirming the lysosome escape and in situ construction of silicon particles in tumor cells, this IHC system was also expected to enhance the in vitro antitumor efficacy through sustained drug release. Subsequently, the cytotoxicity of the IHC system at 24 h and 72 h were investigated with CCK-8 assay in EJ, RT-112 and T24 human bladder cancer cell lines [23] (Figure 2d 2e). However, when the cells were first treated with drugs for 24 h followed by replacement of the culture solutions with fresh drug-free medium and further culture for another 48 h, Dox-PS exhibited sustained cytotoxicity against EJ, RT-112 and T24 cells until 72 h (IC 50 : 36.1, 115.0 and 60.4 nM), whereas Dox-P (IC 50 : 166.4, 388.3 and 313.9 nM) and Dox (IC 50 : 147.0, 394.4 and 281.4 nM) exhibited an obvious decline in cytotoxicity (Figure 2f).…”

Intracellular Self‐Assembly of Peptide Conjugates for Tumor Imaging and Therapy

“…In a recent work, Qiao et al designed a novel peptide-CPT conjugate capable of in situ constructing fibrous drug depots to suppress tumor recurrence. [62] As shown in Figure 5A, the peptidebased prodrug, CPT-LVFFGFLG-PEG-RGD (CPT-LFPR, 5), was composed of a hydrophobic tumor drug CPT, a -sheet peptide (LVEF), a cathepsin B cleavable peptide (GFLG), and a targeting motif (PEG-RGD). Owning to synergistic effect of RGD targeting and EPR effect, the as-prepared nanoparticles of 5 could selectively accumulate at the tumor site.…”